- The Shield test demonstrated 100% sensitivity in detecting colorectal cancer at stages 2 or later. However, it was less effective at detecting stage 1 cancer and did not reliably detect precancerous polyps.
- Despite its limitations, experts believe the test could be a valuable addition to colorectal cancer screening tools. It may be particularly beneficial for the over 50 million eligible Americans who currently do not undergo recommended screenings due to the inconvenience or unpleasantness of existing methods.
- AmirAli Talasaz, co-CEO of Guardant Health, expressed confidence that an accurate blood test could significantly reduce preventable colorectal cancer deaths.
- While the test shows promise, experts recommend that it should not replace screening methods like colonoscopy that can actually prevent cancer.
- The Shield test represents a potential advancement in colorectal cancer screening, especially for those who avoid current screening methods, but it is not seen as a replacement for more comprehensive screening techniques.
In large trial, Guardant Health’s blood test detects colon cancer, but less reliably at earliest or precancerous stages (STAT)
0